Baicheng Pharmaceutical: Innovative drug BIOS-0625 tablets received clinical trial approval.

Official announcement from Baicheng Pharmaceuticals: The innovative drug BIOS-0625 developed independently by the company has obtained the clinical trial approval notification from the National Medical Products Administration. The drug is classified as Class 1 for registration, indicated for the treatment of ulcerative colitis. On August 28, 2025, the National Medical Products Administration accepted the clinical trial application for BIOS-0625 and approved the clinical trial for the treatment of ulcerative colitis.